ProfileGDS5678 / 1439494_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 47% 45% 45% 43% 44% 47% 48% 45% 44% 45% 46% 44% 45% 45% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.138847
GSM967853U87-EV human glioblastoma xenograft - Control 23.0533945
GSM967854U87-EV human glioblastoma xenograft - Control 33.0571545
GSM967855U87-EV human glioblastoma xenograft - Control 42.9503943
GSM967856U87-EV human glioblastoma xenograft - Control 52.9656444
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1905647
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2142448
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0421145
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9913344
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0215445
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0622646
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9929944
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0596845
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0452345